Cure My Disease

Don't miss your cure!

 Log in / Sign up

Targeted chemotherapy pump takes fight directly to pancreatic cancer liver tumors

NCT ID NCT03856658

Disease control Sponsor: Corewell Health West Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This study tests whether delivering a chemotherapy drug called floxuridine directly to the liver through a surgically placed pump can better control tumors that have spread from pancreatic cancer. Participants also receive standard chemotherapy. The goal is to see if this combination can slow or stop liver tumor growth and improve survival.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
floxuridine delivered via a hepatic artery infusion pump
What this could lead to
If successful, this approach could improve control of liver metastases and extend survival for people with pancreatic cancer that has spread to the liver.
What could go wrong
This is a small, early-phase study, so results may not apply broadly. The treatment involves surgery and carries risks such as infection, liver damage, or complications from the pump.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

14 people

The number who actually took part.

Started

Feb 2019

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Biopsy-proved pancreatic adenocarcinoma with synchronous liver metastases * Elevated Cancer Antigen 19-9 (CA19-9) at diagnosis (\>37 U/mL) * Ages 18-75 years * Karnofsky performance status ≥70 * Ability to undergo general anesthesia and HAI pump placement procedure * CT or MRI scan imaging of the abdomen demonstrating accessibility of the gastroduodenal artery within 2 months of enrollment * Received a minimum of 2 months of systemic chemotherapy with stable tumor markers and imaging. Exclusion Criteria: * Primary tumor resected * Model for End Stage Liver Disease (MELD) score \>20, using the variables of: Bilirubin, serum Sodium, International Normalized Ratio (INR), serum Creatinine, and Dialysis twice in the past week. * Greater than 60% liver parenchymal involvement by tumor * Evidence of peritoneal metastases * Current alcohol abuse * Pregnant or lactating women

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Liver metastases are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pancreatic adenocarcinoma pancreatic ductal adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Liver metastases Pancreatic adenocarcinoma

Contacts and locations

Locations

  • Corewell Health West

    Grand Rapids, Michigan, 49503, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.